{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-295491","form_type":"8-K","ticker":"TCRT","cik":"0001107421","company_name":"Alaunos Therapeutics, Inc.","filed_at":"2022-11-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:49.631329+00:00","generated_at":"2026-06-21T11:27:48.468682+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Alaunos Therapeutics prices $15.7M public offering of 24.2M shares at $0.62/share","bullets":["Priced 24,228,719 shares at $0.6191 per share for gross proceeds of $15.7M.","Net proceeds expected ~$14.6M after underwriting discounts and estimated expenses.","Underwriter granted 30-day option to purchase up to 3,634,307 additional shares.","Proceeds to fund continued development of product candidates and for working capital.","Offering expected to close on or about December 1, 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-295491","json":"https://secwatch.observer/filing/0001193125-22-295491.json","markdown":"https://secwatch.observer/filing/0001193125-22-295491.md","text":"https://secwatch.observer/filing/0001193125-22-295491.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1107421/000119312522295491/0001193125-22-295491-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1107421/000119312522295491/d424988d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T11:27:48.468682+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"80490e341707c3ec57e2d0ba8f946534191edf12","claim":"Alaunos Therapeutics, Inc. entered into Underwriting Agreement with Cantor Fitzgerald & Co. valued at approximately $14.6 million (effective 2022-11-29).","evidence_excerpt":"On November 29, 2022, Alaunos Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Cantor Fitzgerald & Co. (the “Underwriter”), as the sole underwriter, relating to the issuance and sale in an underwritten offering (the “Offering”) of 24,228,719 shares (the “Firm Shares”) of the Company’s common stock, par value $0.001 per share, to the Underwriter at a price of $0.6191 per share.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1107421/000119312522295491/0001193125-22-295491-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"underwriting"},{"label":"Counterparty","value":"Cantor Fitzgerald & Co."},{"label":"Value","value":"approximately $14.6 million"},{"label":"Effective","value":"2022-11-29"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}